42067-12-9Relevant academic research and scientific papers
Cobalt-catalyzed intermolecular oxidative isocyanide insertion with two amines: An approach to guanidines
Zhu, Tong-Hao,Wang, Shun-Yi,Wei, Tian-Qi,Ji, Shun-Jun
, p. 823 - 828 (2015)
A novel and efficient cobalt-catalyzed oxidative isocyanide insertion with amines via two C-N bond formation reactions under ultrasound irradiation conditions has been developed. This protocol provides a simple, clean and general way to synthesize guanidines or their corresponding hydrochlorides from simple starting materials under ultrasonic conditions. This chemistry could also be applied to an efficient synthesis of optically active guanidines without loss of enantioselectivity.
De novodesign and synthesis of dipyridopurinone derivatives as visible-light photocatalysts in productive guanylation reactions
Gao, Wenjing,Ma, Nana,Wan, Yameng,Wu, Hao,Zhang, Guisheng,Zhang, Zhiguo,Zhao, Jie
, p. 15988 - 15997 (2021/12/30)
Described here is thede novodesign and synthesis of a series of 6H-dipyrido[1,2-e:2′,1′-i]purin-6-ones (DPs) as a new class of visible-light photoredox catalysts (PCs). The synthesizedDP1-5showed theirλAbs(max)values in 433-477 nm, excited state redox potentials in 1.15-0.69 eV and ?1.41 to ?1.77 eV (vs.SCE), respectively. As a representative,DP4enables the productive guanylation of various amines, including 1°, 2°, and 3°-alkyl primary amines, secondary amines, aryl and heteroaryl amines, amino-nitrile, amino acids and peptides as well as propynylamines and α-amino esters giving diversities in biologically important guanidines and cyclic guanidines. The photocatalytic efficacy ofDP4in the guanylation overmatched commonly used Ir and Ru polypyridyl complexes, and some organic PCs. Other salient merits of this method include broad substrate scope and functional group tolerance, gram-scale synthesis, and versatile late-stage derivatizations that led to a derivative81exhibiting 60-fold better anticancer activity against Ramos cells with the IC50of 0.086 μM than that of clinical drug ibrutinib (5.1 μM).
